Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study

Abstract Background The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Yi‐Hsin Liang, Kuo‐Hsing Chen, Yu‐Yun Shao
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2023-07-01
Цуврал:	Cancer Medicine
Нөхцлүүд:	bevacizumab cetuximab EGFR metastatic colorectal cancer panitumumab secondary surgery
Онлайн хандалт:	https://doi.org/10.1002/cam4.6196
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!